Skip to main content

Table 3 Comparisons of stage of chronic kidney disease between baseline and post

From: Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients

Stage of CKD (%, n/N)

Full cohort with complete case

Propensity score-matched cohort

MM group

Control group

P value

MM group

Control group

P value

Stage 1 (baseline) to stage 2 or above (post)

21.98 % (624/2839)

21.72 % (260/1197)

0.856

23.26 % (258/1109)

21.07 % (237/1125)

0.211

Stage 2 (baseline) to stage 3 or above (post)

10.62 % (431/4058)

6.89 % (156/2 264)

<0.001*

11.09 % (223/2011)

6.66 % (132/1981)

<0.001*

Stage 3 (baseline) to stage 4 or above (post)

10.74 % (64/596)

9.73 % (33/339)

0.629

11.43 % (32/280)

9.18 % (27/294)

0.376

Total

14.93 % (1119/7493)

11.82 % (449/3800)

<0.001*

15.09 % (513/3400)

11.65 % (396/3400)

<0.001*

  1. MM metformin monotherapy, CKD chronic kidney disease, eGFR estimated glomerular filtration rate
  2. Stage 1 CKD (eGFR ≥90 ml/min/1.73 m2); Stage 2 CKD (eGFR ≥60 & <90 ml/min/1.73 m2); Stage 3 CKD (eGFR ≥30 & <60 ml/min/1.73 m2)
  3. Stage 4 CKD (eGFR ≥15 & <30 ml/min/1.73 m2); Stage 5 CKD (eGFR <15 ml/min/1.73 m2)
  4. * Significant with p value <0.05 by Chi-square test